TFS Capital’s Harvard Bioscience HBIO Stock Holding History

TFS Capital’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-4,092	Closed	-$104K	–	150
2017 Q2	$104K	Buy	4,092 +988	+32%	+$24.4K	0.04%	541
2017 Q1	$81K	Sell	3,104 -2,303	-43%	-$66.3K	0.03%	606
2016 Q4	$165K	Buy	5,407 +2,165	+67%	+$55.1K	0.04%	566
2016 Q3	$88K	Sell	3,242 -11,166	-77%	-$310K	0.02%	668
2016 Q2	$412K	Buy	+14,408	New	+$458K	0.08%	434
2015 Q3	–	Sell	-9,865	Closed	-$562K	–	957
2015 Q2	$562K	Buy	+9,865	New	+$561K	0.05%	485
2013 Q4	–	Sell	-5,583	Closed	-$223K	–	1535
2013 Q3	$223K	Sell	5,583 -8,278	-60%	-$326K	0.01%	1217
2013 Q2	$494K	Buy	+13,861	New	+$531K	0.02%	900

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPC

Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Foundry Partners Minneapolis, Minnesota $1.89B AUM 9.84% 1-Year Est. Return

TFS Capital's HBIO Position: Q3 2017 in Review

TFS Capital sold out of Harvard Bioscience (HBIO) in Q3 2017, closing a stake of 4,092 shares — an estimated $104K sold.

TFS Capital first reported a position in HBIO in Q2 2013 and held it in 8 quarters. The position peaked at $562K in Q2 2015. 53 funds tracked by Wall St. Rank hold HBIO as of Q3 2017.

TFS Capital reported no remaining Harvard Bioscience position as of Q3 2017 after selling out during the quarter.
TFS Capital sold 4,092 Harvard Bioscience shares in Q3 2017, an estimated $104K.
TFS Capital first reported a position in Harvard Bioscience in Q2 2013 and held it in 8 quarters.
TFS Capital's Harvard Bioscience position peaked at $562K in Q2 2015.
53 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.